Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avastin: Blood flow paradox

Last week's positive Phase III data for Genentech Inc.'s Avastin bevacizumab anti-VEGF antibody could revive the ailing field of anti-angiogenesis therapy in cancer. But it may not work the way most people think. While Avastin truly does act on tumor blood supply, new research suggests it may not be restricting blood flow. Instead, blockage of VEGF actually may increase blood flow to tumors, thereby improving the efficiency of chemotherapy.

Before Avastin's success in patients with colorectal cancer, the concept of anti-angiogenesis

Read the full 814 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers